Welcome to our dedicated page for NextPlat SEC filings (Ticker: NXPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NextPlat's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NextPlat's regulatory disclosures and financial reporting.
NextPlat Corp reported lower revenue but sharply improved profitability for the three and six months ended June 30, 2026. Quarterly revenue fell to $11.9 million from $13.2 million, and year‑to‑date revenue declined to $21.7 million from $27.2 million, driven mainly by reduced healthcare prescription volumes and reimbursement rates. e‑Commerce revenue was roughly flat.
Mix shift and new contracts significantly improved margins. Gross margin rose to 40% in the quarter and 37% year‑to‑date, versus 22% and 21% a year earlier, helped by higher‑margin 340B and medication‑fulfillment contracts and the Medicare Maximum Fair Price program. Net loss narrowed to $0.1 million for the quarter and $1.3 million year‑to‑date, from $1.8 million and $3.7 million, respectively.
The company held $11.9 million of cash and $14.2 million of working capital, and has $3.8 million of remaining capacity under an at‑the‑market equity program. Management concluded that these resources and its plans alleviate prior substantial doubt about continuing as a going concern. NextPlat also recorded a $1.75 million legal accrual related to a Delaware class action and disclosed ongoing material weaknesses in internal control, along with a $0.4 million liquidated‑damages obligation under a registration rights agreement.
NextPlat Corp reported substantially improved results for the quarter ended June 30, 2026. Quarterly revenue was $11.9 million, up approximately 21% sequentially from $9.9 million, driven by growth in contracted healthcare services and a 27% sequential increase in e-commerce revenue to $4.1 million. Contracted pharmacy revenue rose to about $2.2 million from $0.9 million in the prior-year quarter, including higher 340B and medication fulfillment revenue, while total pharmacy prescription revenue declined to $5.6 million from $8.2 million due to lower reimbursement rates and payer mix.
Overall gross margin reached a record 40%, up from 35% in the first quarter of 2026 and 22% a year earlier. Healthcare Operations gross margin increased to 46% and e-Commerce margin to 27%. Net loss attributable to common stockholders narrowed to $144,000 (loss of $0.05 per share) from $1.8 million (loss of $0.69 per share), and management states that excluding a one-time $0.5 million increase in professional fees, the company was profitable in the quarter.
NextPlat ended the period with $11.9 million in cash, working capital of $14.2 million, and no material unsecured debt. The company highlighted growing 340B prescription volumes, new contracted entities, government and military e-commerce sales exceeding $1.75 million year-to-date, a planned pharmacy acquisition in Florida, and an expected nationwide medication fulfillment website launch in the third quarter of 2026.
NextPlat Corp, through indirect subsidiary Progressive Care, LLC, agreed on July 14, 2026 to acquire 100% of the membership interests in Scott’s Pharmacy, LLC, a community pharmacy in Molino, Florida, for $1.5 million in cash, subject to a post-signing inventory adjustment. An initial $50,000 deposit is placed in escrow and credited at closing; at closing the Seller receives the balance and a further $50,000 is held in escrow for 18 months to secure indemnification obligations. Closing is targeted by September 30, 2026, with a one-time extension to October 31, 2026 for an additional $50,000 deposit, and is conditioned on a 30‑day due diligence review, securing a lease for the premises, required consents, regulatory approvals, and customary representations and covenants. The Seller will sign a three‑year Noncompetition Agreement covering Escambia County, Florida.
The acquired pharmacy has served its rural community for over 25 years and generated approximately $5.6 million in 2025 sales with retail margins of about 19%, remaining profitable with positive working capital and no debt. NextPlat’s Healthcare Operations produced about $39.7 million of the Company’s $54.3 million 2025 revenue, and the Company expects roughly 20% organic growth in 2026, supported by higher‑margin 340B and other contracted services. The acquisition is intended to extend PharmcoRx’s footprint into underserved northwest Florida and provide a platform to introduce same‑day delivery, online fulfillment and expanded services for regional providers and patients.
NextPlat Corp director Rodney Barreto reported receiving a stock grant. On June 30, 2026, he acquired 1,886 shares of Common Stock as a grant, award, or other acquisition at a stated price of $0.00 per share.
Following this grant, Barreto directly holds 471,795 shares of NextPlat Corp common stock, according to the filing. This is a compensation-related equity award rather than an open-market purchase or sale.
Armas Anthony reported acquisition or exercise transactions in this Form 4 filing.
NextPlat Corp director-related entity receives stock grant. An entity associated with director Anthony Armas, Apollo Two MSO, LLC, was granted 943 shares of NextPlat Corp common stock on June 30, 2026 at a stated price of $0.00 per share. Following this grant, Apollo Two MSO, LLC holds 114,259 shares of NextPlat Corp common stock indirectly for Armas.
NextPlat Corp director Douglas Ellenoff received a grant of 1,886 shares of Common Stock on June 30, 2026. The award is classified as a “Grant, award, or other acquisition” and was issued at a price of $0.0000 per share, indicating a compensation-related grant rather than an open-market purchase. Following this transaction, Ellenoff directly holds 192,386 shares of NextPlat common stock.
NextPlat Corp reported the results of its 2026 Annual Meeting of stockholders held on June 24, 2026. Stockholders representing 1,685,403 shares of common stock, or about 62.23% of the 2,708,507 shares outstanding as of April 27, 2026, were represented at the meeting.
All director nominees, including Chairman Rodney Barreto and CEO David Phipps, were elected by wide margins, with each receiving over 1.24 million votes in favor. Other proposals described in the company’s April 30, 2026 proxy statement were also approved, including items that received 1,683,296 votes for with 1,516 against and 591 abstentions.
NextPlat Corp registers 2,097,011 shares of common stock for resale by selling securityholders. The prospectus states the company will not receive any proceeds from these sales and that the registered shares were acquired in private placements between 2019 and 2023.
The prospectus notes 2,708,507 shares outstanding as of June 1, 2026 and discloses a June 1, 2026 closing price of $6.64 per share. It warns that the registered shares are material relative to outstanding shares and that sales could create market overhang while the registration remains effective.
NextPlat Corp filed an amended registration statement and preliminary prospectus to register for resale up to 2,097,011 shares of Common Stock by existing selling securityholders. The resale shares were acquired in private placements from 2019–2023 and the company will not receive proceeds from these resales. The filing notes a 1-for-10 reverse stock split effective April 13, 2026, which reduced outstanding shares to approximately 2,708,507 shares as of June 1, 2026. The prospectus discloses recent net losses of $10.5 million for 2025 and $22.5 million for 2024 and warns that the number of shares being registered for resale is significant relative to outstanding shares and could depress the market price while the registration statement remains effective.